Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring
the movement of individual proteins in living cells.

Eikon’s live cell imaging drug discovery platform is built on groundbreaking innovations from its founders who pioneered the field of in vivo single-molecule microscopy, and whose work was awarded the Nobel Prize in Chemistry in 2014.

• Industry

  • 3D Imaging
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2019

• Founders

  • Eric Betzig
  • Robert Tjian
  • Luke Lavis
  • Xavier Darzacq

  LUX Partners

  • Josh Wolfe

• Latest Tweets

  • Our Chief Scientific Officer Daniel J Anderson is speaking at the @sbi2_org conference in Boston this week. Drop by… https://t.co/UWmL5AxBXv@EikonTX - 02:41 PM Sep 19th
  • Why does Hilary love working at Eikon? “It’s thrilling to be a part of the first discovery research organization e… https://t.co/SJnO8Dk7kx@EikonTX - 03:28 PM Aug 19th
  • Our understanding of biology has been based on visualization tools that provide static snapshots of a moment in tim… https://t.co/qpyveShkVR@EikonTX - 03:59 PM Aug 15th